|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Prodromal Parkinson’s disease: hype or hope for disease-modification trials?显示文摘The ultimate goal in Parkinson’s disease (PD) research remains the identification of treatments that are capable of slowing or even halting the progression of the disease. The failure of numerous past disease-modification trials in PD has been attributed to a variety of factors related not only to choosing wrong interventions, but also to using inadequate trial designs and target populations. In patients with clinically established PD, neuronal pathology may already have advanced too far to be modified by any intervention. Based on such reasoning, individuals in yet prediagnostic or prodromal disease stages, may provide a window of opportunity to test disease-modifying strategies. There is now sufficient evidence from prospective studies to define diagnostic criteria for prodromal PD and several approaches have been studied in observational cohorts. These include the use of PD-risk algorithms derived from multiple established risk factors for disease as well as follow-up of cohorts with single defined prodromal markers like hyposmia, rapid eye movement sleep behavior disorders, or PD gene carriers. In this review, we discuss recruitment strategies for disease-modification trials in various prodromal PD cohorts, as well as potential trial designs, required trial durations, and estimated sample sizes. We offer a concluding outlook on how the goal of implementing disease-modification trials in prodromal cohorts might be achieved in the future. | Philipp Mahlknecht Kathrin Marini Mario Werkmann Werner Poewe Klaus Seppi | 2022 | Translational Neurodegeneration2022，11，1： | 2 |
| 2 | The ostrich effect: Selective attention to information显示文摘 | Niklas Karlsson George Loewenstein Duane Seppi | 2009 | Journal of Risk and Uncertainty2009，，2： | 2 |
| 3 | Liquidity provision with limit orders and a strategic specialist显示文摘 | Seppi D J | 1997 | Review of Financial Studies1997，10，1： | 1 |
| 4 | Progression of multiple system atrophy(MSA) : aprospectivenalural history by the European MSA study Group( EMSA SG) 显示文摘 | Geser F wenning G K Seppi K | 2006 | Mov Disord2006，21，2： | 1 |
| 5 | MRI for the differential diagnosis of neurodegenerative parkinsonism in clinical practice显示文摘 | Seppi K | 2007 | Parkinsonism Relat Disord2007，13，3： | 1 |
| 6 | Voxel-wise analysis of diffusion weighted imaging reveals disruption of the olfactory tract in Parkinson's disease显示文摘 | Scherfler C Schocke MF Seppi K | 2006 | Brain2006，129，2： | 1 |
| 7 | Common factors in prices,order flows and liquidity显示文摘 | Hasbrouck J Seppi D | 2001 | Journal of Financial Economics2001，59，： | 1 |
| 8 | An update on conventional and advanced magnetic resonance imaging techniques in the differential diagnosis of neurodegenerative parkinsonism显示文摘 | Seppi K Schocke M F | 2005 | Curr Opin Neurol2005，18，4： | 1 |
| 9 | Enlarged hyperechogenic substantia nigra as a risk marker for Parkinson’s disease显示文摘 | Berg D Behnke S Seppi K | 2013 | Mov Disord2013，28，： | 1 |
| 10 | Progression of muhiple system atrophy (MSA) :a prospective natural history study by the European MSA Study Group (EMSA SG) 显示文摘 | Geser F Wenning GK Seppi K | 2006 | Mov Disord2006，21，： | 1 |
| 11 | Long-term antidyskinetic efficacy of amantadine in Parkinson' s disease显示文摘 | Wolf E MD Seppi K Katzenschlager R | 2010 | Mov Disord2010，25，10： | 1 |
| 12 | Common factors in prices,order flows,and liquidity显示文摘 | Hasbrouck Seppi | | 0，，03： | 1 |
| 13 | Enlarged substantia nigra hyperechogenicity and risk for Parkinson disease= a 37 month 3 center study of 1847 older persons显示文摘 | Berg D Seppi K Behnke S | 2011 | Arch Neurol2011，68，7： | 1 |
| 14 | Long - term antidyskinetic efficacy of amantadine in Parkinson ' s disease 显示文摘 | Wolf E Seppi K Katzenschlager R | 2010 | Mov Disord2010，25，： | 1 |
| 15 | A Bayesian approach to query optimization in large scale databases显示文摘 | K Seppi J Barnes C Morris | 1993 | ORSA J of Computing1993，1993，： | 1 |
| 16 | The Chemical Composition of Pure Fui Juices显示文摘 | F de Franceco A Seppi | 1997 | Rivista DellaSocieta Italiana Disclenza Dell Alimentzaione1997，6，2： | 1 |
| 17 | Futures manipulation with cash settlement显示文摘 | Kumar Ptaveen Seppi Duane | 1992 | The Journal of Finance1992，47，4： | 1 |
| 18 | Futures manipulation with cash settlement显示文摘 | Kumar P Seppi D | 1992 | Journal of Finance1992，47，4： | 1 |
| 19 | Characterization of the hypertonically induced tyrosine phosphorylation of erythrocyte band 3显示文摘 | Minetti G Seppi C Ciana A | 1998 | Biochem J1998，335，2： | 1 |
| 20 | Drug safety evaluation of rotigotine显示文摘 | Sprenger FS Seppi K Poewe W | 2012 | Expert Opin Drug Saf2012，11，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员